Literature DB >> 19621445

Treatment with sirolimus ameliorates tacrolimus-induced autoimmune cytopenias after solid organ transplant.

David T Teachey1, Tracey Jubelirer, H Jorge Baluarte, Amanda Wade, Catherine S Manno.   

Abstract

The development of autoimmune blood cell cytopenias is a potentially life-threatening complication of solid organ transplantation, resulting from T-cell dysregulation from immunosuppressive medications. Conventional treatment with corticosteroids and IVIgG is often unsuccessful as these therapies are unlikely to overcome the T-cell dysregulation. We describe two patients who developed severe autoimmune cytopenias after solid organ transplantation. They had limited response to conventional medications, but had complete resolution of autoimmunity upon transition of immunosuppression from tacrolimus to sirolimus. Altering the immunosuppressive regimen to modify T-cell dysregulation may be beneficial for patients who develop post-transplant autoimmune disease and allow continued preservation of allograft.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19621445     DOI: 10.1002/pbc.22183

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  6 in total

1.  A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects.

Authors:  Ellen Kraig; Leslie A Linehan; Hanyu Liang; Terry Q Romo; Qianqian Liu; Yubo Wu; Adriana D Benavides; Tyler J Curiel; Martin A Javors; Nicolas Musi; Laura Chiodo; Wouter Koek; Jonathan A L Gelfond; Dean L Kellogg
Journal:  Exp Gerontol       Date:  2018-02-03       Impact factor: 4.032

Review 2.  Diagnosis and management of autoimmune cytopenias in childhood.

Authors:  David T Teachey; Michele P Lambert
Journal:  Pediatr Clin North Am       Date:  2013-10-05       Impact factor: 3.278

3.  Treatment and outcomes of immune cytopenias following solid organ transplant in children.

Authors:  Michelle Schoettler; Scott A Elisofon; Heung Bae Kim; Elizabeth D Blume; Nancy Rodig; Debra Boyer; Ellis J Neufeld; Rachael F Grace
Journal:  Pediatr Blood Cancer       Date:  2014-10-12       Impact factor: 3.167

Review 4.  Autoimmune lymphoproliferative syndrome: more than a FAScinating disease.

Authors:  Karen Bride; David Teachey
Journal:  F1000Res       Date:  2017-11-01

Review 5.  Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.

Authors:  David Barrett; Valerie I Brown; Stephan A Grupp; David T Teachey
Journal:  Paediatr Drugs       Date:  2012-10-01       Impact factor: 3.930

Review 6.  Rehabilitation in Pediatric Heart Failure and Heart Transplant.

Authors:  Ana Ubeda Tikkanen; Emily Berry; Erin LeCount; Katherine Engstler; Meredith Sager; Paul Esteso
Journal:  Front Pediatr       Date:  2021-05-19       Impact factor: 3.418

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.